UK Approves Novo Nordisk's Oral Wegovy Weight-Loss Pill, Private Prescriptions Expected Within Weeks
Taylor Wilson
Britain's MHRA has approved Novo Nordisk's oral Wegovy tablet, with private prescriptions expected within weeks. This means the weight-loss drug race has officially moved from needles to pills — and Novo Nordisk's first-mover lead over Eli Lilly keeps widening.
Who is this pill approved for?
Two tiers: obese adults with BMI ≥ 30, and those with BMI 27–30 plus at least one weight-related condition.
The active ingredient is semaglutide — a molecule that mimics GLP-1, the body's own satiety hormone — identical to the injectable Wegovy and the diabetes drug Ozempic.
In plain terms = same drug, new format — the molecule hasn't changed, only the delivery method.
When can UK patients actually get it?
Novo Nordisk expects availability via private prescriptions within weeks — meaning patients who pay out of pocket can access it first.
Broader access through the NHS still requires a cost-effectiveness review by NICE, the UK's health-technology assessor.
This means → only self-paying patients get early access; mass rollout hinges on the NICE verdict.
How far ahead is Novo Nordisk over Eli Lilly?
Novo Nordisk secured US FDA approval for oral Wegovy last December, more than three months ahead of Lilly.
Lilly's oral weight-loss drug orforglipron (brand name Foundayo) — a once-daily, non-peptide GLP-1 agonist distinct from semaglutide's peptide structure — won US approval only in April. In a late-stage trial, the highest-dose group lost 12.4% of body weight over 72 weeks.
The European Medicines Agency (EMA) recommended approval of oral Wegovy in May, clearing the path to the EU market. This reflects Novo Nordisk locking in first-mover positions across the US, UK, and Europe.
What does this mean for the weight-loss drug market?
Wall Street had widely projected the global weight-loss drug market to reach $150 billion within the next decade.
But generic competition is approaching, and both Novo Nordisk's and Lilly's blockbuster injectables face pricing pressure in the US — prompting analysts to revisit that forecast.
This means → the oral format opens the door to new patient pools, yet price erosion and generics may squeeze margins at the same time — the market is growing, but how the pie gets divided is far from settled.
Content is for reference only, not financial advice.